The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials

Am J Bioeth. 2011 Mar;11(3):18-9. doi: 10.1080/15265161.2011.552357.
No abstract available

Publication types

  • Comment

MeSH terms

  • Amifostine / therapeutic use
  • Child
  • Clinical Trials Data Monitoring Committees*
  • Clinical Trials, Phase III as Topic / methods
  • Clinical Trials, Phase III as Topic / standards*
  • Early Termination of Clinical Trials
  • Hepatoblastoma / drug therapy
  • Humans
  • Liver Neoplasms / drug therapy
  • Radiation-Protective Agents / therapeutic use
  • Randomized Controlled Trials as Topic / methods
  • Randomized Controlled Trials as Topic / standards*
  • Research Design / standards*
  • Rhabdomyolysis / chemically induced
  • Time Factors
  • Treatment Outcome*

Substances

  • Radiation-Protective Agents
  • Amifostine